文献速递心力衰竭与心肌病心律失常

干细胞来源心肌细胞与β肾上腺素受体阻滞在杜氏肌营养不良心肌病中的应用

Stem Cell-Derived Cardiomyocytes and Beta-Adrenergic Receptor Blockade in Duchenne Muscular Dystrophy Cardiomyopathy.
PubMed 文献 · J Am Coll Cardiol · 2020-01-01

本研究利用杜氏肌营养不良(DMD)患者特异性人诱导多能干细胞(hiPSC)来源心肌细胞及mdx小鼠模型,探讨肾上腺素能激动剂与β阻滞剂的生理反应。DMD hiPSC来源心肌细胞在基线和肾上腺素能刺激后心律失常性钙瞬变显著增加,普萘洛尔可显著减少;mdx小鼠在异丙肾上腺素刺激下出现心律失常性死亡,普萘洛尔预处理可部分挽救。转录组分析显示DMD hiPSC来源心肌细胞通路失调与人类DMD心脏相似,且相对少数DMD患者就诊心血管专科或接受β阻滞剂治疗。

要点

  • DMD患者hiPSC来源心肌细胞存在心律失常性钙瞬变增加,普萘洛尔可减少。
  • mdx小鼠异丙肾上腺素刺激可致心律失常性死亡,普萘洛尔预处理可部分挽救。
  • DMD hiPSC来源心肌细胞通路失调与人类DMD心脏相似。

核心结论

  • DMD hiPSC来源心肌细胞和mdx小鼠模型揭示了营养不良心脏的机制与治疗干预,普萘洛尔可减少心律失常。
  • 结果可能为一项充分把握度的临床研究前奏,以检验β阻滞剂在肌营养不良蛋白病患者中的影响。

研究设计与样本

  • 使用DMD患者特异性hiPSC来源心肌细胞研究对肾上腺素能激动剂和β阻滞剂的生理反应。
  • 进一步在野生型和mdx小鼠模型中体内检验这些药物。

主要发现

  • 基线和肾上腺素能刺激后,DMD hiPSC来源心肌细胞心律失常性钙瞬变较同基因对照显著增加。
  • 普萘洛尔治疗显著减少这些心律失常。
  • mdx小鼠在异丙肾上腺素刺激下出现心律失常性死亡,普萘洛尔预处理部分挽救致死性心律失常。
  • 单细胞和bulk RNA测序比较DMD与对照hiPSC来源心肌细胞、mdx与对照小鼠,定义基线扰动及普萘洛尔治疗后正常化的通路。
  • 人类DMD左心室样本转录组分析显示DMD hiPSC来源心肌细胞通路失调与人类DMD心脏相似。

临床怎么用

  • 提示β阻滞剂可能减少DMD心肌病中的心律失常,但需充分把握度的临床研究验证。
  • DMD患者中就诊心血管专科和接受β阻滞剂治疗的比例相对较少,提示存在治疗缺口。

局限性

  • 研究主要为细胞和动物模型,人类数据限于转录组分析和治疗现状描述,尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although cardiomyopathy has emerged as a leading cause of death in Duchenne muscular dystrophy (DMD), limited studies and therapies have emerged for dystrophic heart failure. OBJECTIVES: The purpose of this study was to model DMD cardiomyopathy using DMD patient-specific human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes and to identify physiological changes and future drug therapies. METHODS: To explore and define therapies for DMD cardiomyopathy, the authors used DMD patient-specific hiPSC-derived cardiomyocytes to examine the physiological response to adrenergic agonists and β-blocker treatment. The authors further examined these agents in vivo using wild-type and mdx mouse models. RESULTS: At baseline and following adrenergic stimulation, DMD hiPSC-derived cardiomyocytes had a significant increase in arrhythmic calcium traces compared to isogenic controls. Furthermore, these arrhythmias were significantly decreased with propranolol treatment. Using telemetry monitoring, the authors observed that mdx mice, which lack dystrophin, had an arrhythmic death when stimulated with isoproterenol; the lethal arrhythmias were rescued, in part, by propranolol pre-treatment. Using single-cell and bulk RNA sequencing (RNA-seq), the authors compared DMD and control hiPSC-derived cardiomyocytes, mdx mice, and control mice (in the presence or absence of propranolol and isoproterenol) and defined pathways that were perturbed under baseline conditions and pathways that were normalized after propranolol treatment in the mdx model. The authors also undertook transcriptome analysis of human DMD left ventricle samples and found that DMD hiPSC-derived cardiomyocytes have dysregulated pathways similar to the human DMD heart. The authors further determined that relatively few patients with DMD see a cardiovascular specialist or receive β-blocker therapy. CONCLUSIONS: The results highlight mechanisms and therapeutic interventions from human to animal and back to human in the dystrophic heart. These results may serve as a prelude for an adequately powered clinical study that examines the impact of β-blocker therapy in patients with dystrophinopathies.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Kamdar F, Das S, Gong W, et al. Stem Cell-Derived Cardiomyocytes and Beta-Adrenergic Receptor Blockade in Duchenne Muscular Dystrophy Cardiomyopathy. J Am Coll Cardiol. 2020. PMID: 32164890. doi:10.1016/j.jacc.2019.12.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。